Armin Rehm, Lars Bullinger, Anne Kerber discuss translating cancer immunotherapies from Berlin labs to the clinic
Armin Rehm, Lars Bullinger, Anne Kerber discuss translating cancer immunotherapies from Berlin labs to the clinic The path of new immunotherapies to the clinic | Max Delbrück Center The path of new immunotherapies to the clinic The two-hour conversation with experts — including cancer researcher Dr. Armin Rehm of the Max Delbrück Center, Professor Lars Bullinger, Head of Tumor Immunology at Charité, and Dr. Anne Kerber, Senior Vice President and Head of Development for Hematology, Oncology, and Cell Therapy at the U.S. pharmaceutical company Bristol Myers Squibb — concludes the series “ Cancer research: How ideas become life-saving therapies.” ...